Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
October 05, 2018 10:01 ET
|
Selecta Biosciences, Inc.; Généthon
Represents a potentially powerful strategy to modulate vector immunogenicity and may open new therapeutic avenues for AAV vector-mediated gene transfer EVRY, France and WATERTOWN, Mass., Oct. 05,...
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer
September 27, 2018 07:30 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018
September 25, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018
September 20, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018
September 10, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)
August 31, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update
August 08, 2018 08:00 ET
|
Selecta Biosciences, Inc.
Expanded three-month Phase 2 data presented at EULAR 2018 continue to indicate that SEL-212 product profile may provide better and more sustained serum uric acid control, fewer flares and less...
Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018
August 02, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call
August 01, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
June 15, 2018 05:30 ET
|
Selecta Biosciences, Inc.
3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA)...